Substance P Research: What 26,728 Studies Show (2026) | RetatrutideCompare

Substance P — 26,728 studies indexed on PubMed. Activates the neurokinin-1 (NK1) receptor — pro-inflammatory, nociceptive transmission. Half-life: Minutes. FDA status: Native peptide not approved; antagonists are.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Substance P?

There are approximately 26,728 studies indexed on PubMed that mention Substance P (SP, Neurokinin 1 ligand), based on a search last updated 2026-06-18.

Is Substance P FDA-approved?

FDA status: Native peptide not approved; antagonists are.

How does Substance P work?

Activates the neurokinin-1 (NK1) receptor — pro-inflammatory, nociceptive transmission.

Reference facts

Also known as: SP, Neurokinin 1 ligand
Category: Neuropeptide & Other
Mechanism of action: Activates the neurokinin-1 (NK1) receptor — pro-inflammatory, nociceptive transmission.
Targets: NK1 receptor
Indications under research or approved: Research target (NK1 antagonists like Aprepitant are antiemetic drugs)
Regulatory status (reference entry): Native peptide not approved; antagonists are
Half-life: Minutes
Sequence: RPKPQQFFGLM
Sequence notes: Undecapeptide with C-terminal amide; member of the tachykinin family.
Molecular weight (Da): 1347
First reported: 1931
Origin: Identified by von Euler and Gaddum in horse brain and intestine extracts.

Primary References

Steinhoff et al., Physiol Rev 2014 (NK1)

Explore research articles about Substance P

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.